Metformin , a biguanide and first-line medication for type 2 diabetes, primarily reduces hepatic glucose production and improves peripheral insulin sensitivity
This initiates a cascade that leads to the activation of protein kinase A (PKA), closing of potassium channels, depolarization, and release of calcium from the endoplasmic reticulum.3 An increase of intracellular calcium levels within the cell initiates insulin expression in the nucleus, stimulates energy (ATP) production in the mitochondria, and triggers the release of insulin into the blood stream in a glucose dependent manner (image adapted from Adipogen Life Sciences).4,5 Several commercially and prescribed agents are now available for the management of obesity and type 2 diabetes
Data regarding the cancer risk associated with tirzepatide are limited in the published RCTs
Adv Drug Delivery Rev 42:225238 Lewis AL, Mcentee N, Holland J, Patel A (2022) Development and approval of rybelsus (oral semaglutide): ushering in a new era in peptide delivery
Decreased risk of comorbid conditions: Conditions like high blood pressure and cardiovascular disease, which are often linked to sleep apnea, improve with weight loss
As GLP-1 therapy improves glucose control, this osmotic effect typically diminishes, potentially normalising previously excessive urination patterns